Vaxcyte (PCVX) Stock Forecast & Price Target

Compare

435 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PCVX Analyst Ratings

Strong Buy

7 Buy

0 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Vaxcyte

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PCVX Stock 12 Month Forecast

Average Price Target

$100.80

▲(130.61% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Vaxcyte in the last 3 months. The average price target is $100.80 with a high forecast of $163.00 and a low forecast of $50.00. The average price target represents a 130.61% change from the last price of $43.71.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"30":"$30","97":"$97","164":"$164","63.5":"$63.5","130.5":"$130.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":163,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$163.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$100.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$50.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[30,63.5,97,130.5,164],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,45.52,54.55692307692308,63.59384615384616,72.63076923076923,81.6676923076923,90.70461538461538,99.74153846153845,108.77846153846153,117.8153846153846,126.85230769230768,135.88923076923075,144.92615384615382,153.96307692307693,{"y":163,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,45.52,49.77230769230769,54.02461538461539,58.27692307692308,62.52923076923077,66.78153846153846,71.03384615384616,75.28615384615385,79.53846153846155,83.79076923076923,88.04307692307692,92.29538461538462,96.5476923076923,{"y":100.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,45.52,45.86461538461539,46.20923076923077,46.55384615384616,46.89846153846154,47.24307692307693,47.58769230769231,47.932307692307695,48.276923076923076,48.621538461538464,48.966153846153844,49.31076923076923,49.65538461538462,{"y":50,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":107.29,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.6,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.86,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.32,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.02,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.23,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.24,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.02,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.56,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.03,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.28,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.52,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$163.00

Average Price Target$100.80

Lowest Price Target$50.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Thomas Shrader

BTIG

$85

Buy

94.46%

Upside

Reiterated

12/09/25

Promising Potential of Vaxcyte's VAX-31 Vaccine Drives Buy Rating

Joseph Stringer

Needham

$90

Buy

105.90%

Upside

Reiterated

12/08/25

Vaxcyte's Strategic Phase 3 Trial Initiation and Its Market ImplicationsWe thought the trial design was in line with expectations and consistent with mgmt's prior guidance. The Ph3 OPUS trial will evaluate V AX-31 in a head-to-head NI comparison to Prevnar20 (20-valent). Topline data from the Ph3 OPUS trial are expected in 4Q25. We caught up with mgmt following the announcement for additional details and provide highlights from our discussion with below. Disclaimers JOSEPH STRINGER, PH.D.

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

$116

Buy

165.39%

Upside

Reiterated

12/08/25

Vaxcyte (PCVX) Gets a Buy from GuggenheimWith the initiation of the VAX-31 Phase 3 trial, we reiterate PCVX as a Top Pick for 2026 with a $116 price target.

Salim Syed

Mizuho Securities

$163

Buy

272.91%

Upside

Reiterated

11/20/25

Mizuho Securities Sticks to Their Buy Rating for Vaxcyte (PCVX)PCVX (OP, maintaining PT at $163): Vaxcyte could become very topical for investors again, as we approach Ph3 VAX-31 adult data in 2026; no material changes to our model.

Jason Gerberry

Bank of America Securities

―

Buy

―

Reiterated

11/05/25

Analysts' Top Healthcare Picks: Charles River Labs (CRL), Vaxcyte (PCVX)

Tara Bancroft

TD Cowen

$50

Buy

14.39%

Upside

Reiterated

11/04/25

Promising Vaccine Trials and Undervaluation Drive Buy Rating for Vaxcyte

David Risinger

Leerink Partners

―

Buy

―

Reiterated

10/01/25

Asad Haider

Goldman Sachs

$38

Hold

-13.06%

Downside

Initiated

09/12/25

Vaxcyte initiated with a Neutral at Goldman SachsVaxcyte initiated with a Neutral at Goldman Sachs

Carter Gould

Cantor Fitzgerald

―

Buy

―

Reiterated

06/10/25

Vaxcyte (PCVX) Receives a Buy from Cantor Fitzgerald

Umer Raffat

Evercore ISI

―

Buy

―

Reiterated

03/31/25

Optimistic Outlook for Vaxcyte: Potential for Improved Vaccine Efficacy in Future Trials

Roger Song

Jefferies

$146

Buy

234.02%

Upside

Reiterated

03/31/25

Jefferies on Vaxcyte (PCVX): this data increasing PCVXs fundamental valueJefferies analyst Roger Song reiterated a Buy rating and $146.00 price target on Vaxcyte (NASDAQ: PCVX).

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Thomas Shrader

BTIG

$85

Buy

94.46%

Upside

Reiterated

12/09/25

Promising Potential of Vaxcyte's VAX-31 Vaccine Drives Buy Rating

Joseph Stringer

Needham

$90

Buy

105.90%

Upside

Reiterated

12/08/25

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

$116

Buy

165.39%

Upside

Reiterated

12/08/25

Vaxcyte (PCVX) Gets a Buy from GuggenheimWith the initiation of the VAX-31 Phase 3 trial, we reiterate PCVX as a Top Pick for 2026 with a $116 price target.

Salim Syed

Mizuho Securities

$163

Buy

272.91%

Upside

Reiterated

11/20/25

Jason Gerberry

Bank of America Securities

―

Buy

―

Reiterated

11/05/25

Analysts' Top Healthcare Picks: Charles River Labs (CRL), Vaxcyte (PCVX)

Tara Bancroft

TD Cowen

$50

Buy

14.39%

Upside

Reiterated

11/04/25

Promising Vaccine Trials and Undervaluation Drive Buy Rating for Vaxcyte

David Risinger

Leerink Partners

―

Buy

―

Reiterated

10/01/25

Asad Haider

Goldman Sachs

$38

Hold

-13.06%

Downside

Initiated

09/12/25

Vaxcyte initiated with a Neutral at Goldman SachsVaxcyte initiated with a Neutral at Goldman Sachs

Carter Gould

Cantor Fitzgerald

―

Buy

―

Reiterated

06/10/25

Vaxcyte (PCVX) Receives a Buy from Cantor Fitzgerald

Umer Raffat

Evercore ISI

―

Buy

―

Reiterated

03/31/25

Optimistic Outlook for Vaxcyte: Potential for Improved Vaccine Efficacy in Future Trials

Roger Song

Jefferies

$146

Buy

234.02%

Upside

Reiterated

03/31/25

Jefferies on Vaxcyte (PCVX): this data increasing PCVXs fundamental valueJefferies analyst Roger Song reiterated a Buy rating and $146.00 price target on Vaxcyte (NASDAQ: PCVX).

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vaxcyte

1 Month

xxx

Success Rate

13/19 ratings generated profit

Average Return

+5.12%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 68.42% of your transactions generating a profit, with an average return of +5.12% per trade.

3 Months

xxx

Success Rate

15/24 ratings generated profit

Average Return

+10.35%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +10.35% per trade.

1 Year

Joseph StringerNeedham

Success Rate

20/30 ratings generated profit

Average Return

+24.25%

reiterated a buy rating 12 days ago

Copying Joseph Stringer's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +24.25% per trade.

2 Years

xxx

Success Rate

20/30 ratings generated profit

Average Return

+79.88%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +79.88% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PCVX Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PCVX has received 12 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. PCVX average Analyst price target in the past 3 months is 100.80.

Each month's total comprises the sum of three months' worth of ratings.

PCVX Financial Forecast

PCVX Earnings Forecast

Next quarter’s earnings estimate for PCVX is -$1.50 with a range of -$1.90 to -$1.17. The previous quarter’s EPS was -$1.56. PCVX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year PCVX has Performed in-line its overall industry.

No data currently available

PCVX Sales Forecast

Next quarter’s sales forecast for PCVX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. PCVX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year PCVX has Performed in-line its overall industry.

PCVX Stock Forecast FAQ

What is PCVX’s average 12-month price target, according to analysts?

Based on analyst ratings, Vaxcyte, Inc.’s 12-month average price target is 100.80.

What is PCVX’s upside potential, based on the analysts’ average price target?

Vaxcyte, Inc. has 130.61% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is PCVX a Buy, Sell or Hold?

Vaxcyte, Inc. has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.

What is Vaxcyte, Inc.’s price target?

The average price target for Vaxcyte, Inc. is 100.80. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $163.00 ,the lowest forecast is $50.00. The average price target represents 130.61% Increase from the current price of $43.71.

What do analysts say about Vaxcyte, Inc.?

Vaxcyte, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of PCVX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Vaxcyte (PCVX) Stock Forecast & Price Target

PCVX Analyst Ratings

PCVX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Vaxcyte

PCVX Analyst Recommendation Trends

PCVX Financial Forecast

PCVX Earnings Forecast

PCVX Sales Forecast

PCVX Stock Forecast FAQ

Detailed List of Analyst Forecasts